...
首页> 外文期刊>International Journal of Pharmaceutics >A lipid-based liquid crystalline matrix that provides sustained release and enhanced oral bioavailability for a model poorly water soluble drug in rats.
【24h】

A lipid-based liquid crystalline matrix that provides sustained release and enhanced oral bioavailability for a model poorly water soluble drug in rats.

机译:基于脂质的液晶基质,可为大鼠中难溶性模型药物提供持续释放和增强的口服生物利用度。

获取原文
获取原文并翻译 | 示例
           

摘要

Liquid crystalline phases that are stable in excess water, formed using lipids such as glyceryl monooleate (GMO) and oleyl glycerate (OG), are known to provide a sustained release matrix for poorly water soluble drugs in vitro, yet there has been no report of the use of these materials to impart oral sustained release behaviour in vivo. In the first part of this study, in vitro lipolysis experiments were used to compare the digestibility of GMO with a second structurally related lipid, oleyl glycerate, which was found to be less susceptible to hydrolysis by pancreatic lipase than GMO. Subsequent oral bioavailability studies were conducted in rats, in which a model poorly water soluble drug, cinnarizine (CIN), was administered orally as an aqueous suspension, or as a solution in GMO or OG. In the first bioavailability study, plasma samples were taken over a 30 h period and CIN concentrations determined by HPLC. Plasma CIN concentrations after administration in the GMO formulation were only sustained fora few hours after administration while for the OG formulation, the plasma concentration of cinnarizine was at its highest level 30 h after dosing, and appeared to be increasing. A second study in which CIN was again administered in OG, and plasma samples taken for 120 h, revealed a Tmax for CIN in rats of 36 h and a relative oral bioavailability of 344% when compared to the GMO formulation (117%) and the aqueous suspension formulation (assigned a nominal bioavailability of 100%). The results indicate that lipids that form liquid crystalline structures in excess water, may have application as an oral sustained release delivery system, providing they are not digested rapidly on administration.
机译:已知使用脂质(如甘油单油酸酯(GMO)和油酸甘油酯(OG))形成的在过量水中稳定的液晶相可为体外水溶性差的药物提供缓释基质,但尚无报道使用这些材料在体内赋予口服缓释行为。在本研究的第一部分中,使用体外脂解实验比较了GMO与第二种结构相关的脂质油酸甘油酯的消化率,该脂质比GMO较不易被胰腺脂肪酶水解。随后在大鼠中进行了口服生物利用度研究,其中以水溶性悬液或在GMO或OG中的溶液形式口服水溶性差的模型药物肉桂那嗪(CIN)。在第一个生物利用度研究中,在30小时内采集血浆样品,并通过HPLC测定CIN浓度。在GMO制剂中,给药后血浆CIN浓度仅在给药后持续数小时,而对于OG制剂,肉桂利嗪的血浆浓度在给药后30小时达到最高水平,并且似乎正在增加。在OG中再次施用CIN并采集血浆样品120小时的第二项研究显示,与GMO制剂(117%)和GMO制剂相比,大鼠CIN的Tmax为36 h,相对口服生物利用度为344%。水性悬浮液制剂(标称生物利用度为100%)。结果表明,在过量的水中形成液晶结构的脂质可以作为口服缓释递送系统应用,只要它们在给药时不被迅速消化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号